Lexicon releases positive Phase II trial results of LX1033 to treat irritable bowel syndrome
US-based biopharmaceutical firm Lexicon Pharmaceuticals has released top-line results from an initial Phase II trial, designed to assess the use of its investigational drug LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Irritable Bowel Syndrome | Pharmaceuticals